Click here to view the original post by Ophthalmology Science.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
To evaluate the safety, tolerability, and ocular hypotensive properties of QLS-111, a preservative-free, novel and proprietary formulation of an ATP-sensitive potassium channel opener, either alone or in combination with approved glaucoma drugs, in preclinical animal models.